CT-2106 for the Second Line Treatment of Ovarian Cancer
Status:
Completed
Trial end date:
2007-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this sudy is to determine the response rate of CT-2106 in patients with
advanced ovarian cancer who have failed one prior platinum and taxane based regimen.